Fresenius Medical Care (FMS) Q3 2026 earnings review
Fresenius Medical Care cuts its profit outlook as treatments fall
Fresenius Medical Care, the world's largest operator of kidney dialysis clinics and maker of dialysis machines, saw its profit shrink while underlying sales stood still. Third-quarter operating income excluding one-offs fell 6% in constant currency to €545 million, and reported net profit dropped 42% after a €108 million write-off to exit product lines in China. Three weeks into the job, new chief executive Shervin J. Korangy cut the top half of the full-year profit plan.
| Sales from businesses owned a year ago | +0.1% from a year ago (€4,937M reported) |
|---|---|
| Operating profit, excluding one-offs | €545M -6% in constant currency |
| U.S. same-market dialysis treatments | -1.1% -0.9% last quarter |
| Full-year operating profit outlook | Cut 0% to -5% (was +5% to -5%) |
⚖️ Verdict: 🔴 Bearish
The story got worse because U.S. clinic treatment volumes shrank faster just as temporary U.S. drug payments turned into a drag. U.S. same-market treatments fell 1.1% against a full-year plan for flat volumes, and by our math the lowered outlook leaves fourth-quarter operating profit excluding one-offs falling about 25%. On the positive side, the U.S. rollout of the 5008X dialysis machine reached 16% of clinic machines, and share buybacks kept profit per share excluding one-offs flat.
The question now is whether the new 5008X machines and cost cuts can lift profit in 2027 after temporary drug payments end. Either the new machines reduce patient mortality and bring U.S. treatment volumes back to growth, or inflation and patient attrition keep shrinking the core clinic base. Management's 2027 outlook in February will show which path the new chief executive sees.
🐂 Bull Case
New U.S. Dialysis Machine Rollout Stays on Track
Fresenius Medical Care is replacing the dialysis machines in its U.S. clinics with the 5008X CAREsystem, a newer machine that filters more toxins from a patient's blood. Finance chief Martin Fischer said the U.S. rollout is progressing on plan and now covers 348 clinics, or 16% of its U.S. machines, keeping the kidney care company on track for its 20% full-year target.
Clinics have now completed 1.3 million treatments on the new machines, up from 100,000 in early April. That rollout helped lift underlying sales in Care Enablement, the medical equipment division, by 5.1% to €1,451 million. Early clinical observations track well against international studies that link the therapy to "fewer hospitalizations, fewer missed treatments, and improved survival compared with conventional hemodialysis".
What to watch: the share of U.S. machines replaced by year-end and the clinical data presentations planned through 2027. Hitting the 20% machine target and showing lower patient mortality would prove the upgrade can eventually reverse falling U.S. clinic volumes.
Cost Cuts and Buybacks Keep Earnings Per Share Flat
Fresenius Medical Care is using cost cuts and share repurchases to protect per-share earnings while drug reimbursement tailwinds fade. Its cost-cutting programme, FME25+, delivered €74 million of savings this quarter toward a €250 million full-year target, helping clinic operating income excluding one-offs grow 2.5% in constant currency to €513 million.
- Net income excluding one-offs: €291 million, down 9.6% from a year ago
- Average share count: 263 million, down 10.0% from a year ago
- Profit per share excluding one-offs: €1.11, up 0.4% from a year ago
Because the German healthcare group bought back 9.1 million shares for €357 million between May and September under its second €1 billion buyback programme, profit per share excluding one-offs stayed flat even as net profit fell. What to watch: completion of the first buyback tranche by December 15, 2026, which will show how much share-count support carries into 2027.
🐻 Bear Case
New CEO Cuts the Top Half of the Profit Plan
Three weeks into the job, chief executive Shervin J. Korangy struck a cautious note on the business. "We are muted in our assessment of performance and endeavor to improve the current trajectory over time," Korangy said. He dropped the upper half of the full-year profit plan, so the kidney care provider now expects operating income excluding one-offs to stay flat or fall up to 5% in constant currency.
In the third quarter, operating income excluding one-offs fell 5.7% in constant currency to €545 million, and the operating margin shrank 0.7 percentage points to 11.0%. Selling and administrative costs rose 0.6 percentage points of revenue to 15.1%, while temporary U.S. government payments for dialysis drugs, known as TDAPA, turned from a tailwind into a drag.
Because operating income excluding one-offs is still up 8.2% in constant currency over the first nine months, the narrowed full-year plan points to a steep drop at year-end. By our math, the middle of the new range implies fourth-quarter operating income excluding one-offs will fall about 25% in constant currency against last year's high base.
What to watch: fourth-quarter operating income excluding one-offs against that implied €526 million middle of the range, by our math. A drop near the bottom of the range would mean inflation and lost drug payments are hitting harder than cost savings can offset.
U.S. Clinic Treatment Volumes Shrank Fast
Care Delivery U.S., the division that runs 2,540 American dialysis clinics and brings in nearly three-fifths of group sales, is losing treatment volume at a faster pace. Management entered 2026 assuming U.S. same-market treatment growth — the change in dialysis sessions at clinics open at least a year — would stay flat for the full year.
Instead, the decline deepened for a third straight quarter. U.S. same-market treatments fell 1.1% from a year ago in the third quarter, worse than the 0.4% drop in the first quarter and the 0.9% drop in the second, leaving nine-month volumes down 0.8%. Higher prices per treatment kept U.S. clinic underlying sales up 1.2%, but finance chief Martin Fischer noted that TDAPA drug payment rules offset those rate gains.
What to watch: U.S. same-market treatment growth in the fourth quarter and the 2027 volume assumption in February. Another drop below 1% would show that clinic closures and patient attrition are shrinking the core U.S. patient base.
China Pullback Triggers €108 Million Write-Off
Chinese government price-cutting tenders have pressured the Care Enablement equipment division all year, and this quarter Fresenius Medical Care pulled back in the country. The dialysis equipment maker refined its Chinese setup by "discontinuing production and sales of the 4008A hemodialysis system locally" and "exited its peritoneal dialysis (PD) business while maintaining existing obligations in the market".
Scrapping equipment, writing down assets and paying termination costs in China cost €108 million in one-off charges. That lifted other operating expenses by 2.3 percentage points of group revenue to 4.9%, dragged Care Enablement into a €32 million reported operating loss, and cut group reported net profit by 42% to €160 million.
What to watch: Care Enablement operating margin excluding one-offs in the fourth quarter, which dipped 0.3 percentage points to 7.3% in the third quarter on inflation. A rebound above 8% would show that exiting the unprofitable Chinese lines stops the drag on the equipment division.
👓 Other Themes
Value-Based Care Contract Change Drags Down Group Sales
Value-Based Care, the division that manages overall medical spending for kidney patients under risk contracts with insurers, saw revenue fall 6.8% to €537 million, or 8.6% on an underlying basis. A contract change lowered the revenue the division books without hurting profit: operating income excluding one-offs reached €1 million, up from a €21 million loss a year ago, as aligned membership fell 7% to 150,040.
💲 Other KPIs
Cash generated from operations rose 7.5% from a year ago to 16.2% of revenue, up from 15.2% last year. Customers paid faster — days sales outstanding, the average time to collect bills, fell by three days from a year ago to 59 days — which lifted free cash flow by 2.5% to €564 million despite higher machine spending.
Net debt including lease obligations rose 6.2% from a year ago and 6.4% from the end of 2025, as the kidney care group spent €400 million on dividends and funded share buybacks. Net debt stood at 2.6 times annual operating profit before depreciation (EBITDA), unchanged from the second quarter and near the bottom of its 2.5 to 3.0 target band.
Head-office costs excluding one-offs swung from a €3 million gain a year ago to a €29 million loss, bringing the nine-month corporate loss to €105 million against €9 million last year. The company spent more on planned information-technology platform upgrades, which outweighed gains from virtual power purchase agreements.
🔮 Guidance
Unchanged. The full-year plan still calls for revenue in constant currency to match the €19,628 million base from 2025. Because constant-currency revenue grew 2.0% in the first nine months to €14,855 million, by our math a flat full year leaves fourth-quarter revenue falling about 5.9% in constant currency, driven by the contract accounting change in Value-Based Care.
Cut. Chief executive Shervin J. Korangy removed the positive half of the prior range, so the plan now has operating profit excluding one-offs between flat and down about 5% from the €2,212 million base in 2025. By our math, the middle of the new range leaves fourth-quarter operating profit falling about 25% in constant currency as temporary U.S. drug payments roll off.
❓ Key Questions
What are new CEO Shervin Korangy's capital and portfolio priorities?
Korangy said many parts of the business are at an early stage of development and that he is muted in his assessment of performance. Investors need to know whether he will alter the 2030 margin targets or slow down share buybacks to fund new investments.
Why did U.S. same-market treatment volumes drop 1.1%?
Management previously expected U.S. treatment volumes to stay flat in 2026, but the decline worsened from 0.4% in the first quarter to 1.1% in the third. The release did not say how much came from patients losing Affordable Care Act insurance subsidies versus clinic closures.
Does the €108 million China charge finish the restructuring there?
Exiting the 4008A dialysis machine and the peritoneal dialysis business in China triggered €108 million in write-offs, double the €50 million full-year portfolio optimization budget set in February. Management did not say how much Chinese revenue remains or if further exits are planned.
Why did internal profit eliminations jump to €46 million?
Operating income eliminated between divisions rose from €4 million a year ago to €46 million in the third quarter, bringing the nine-month total to €107 million. How much of that charge comes from shipping 5008X machines to internal U.S. clinics, and when does it peak?